Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

 Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Chugai Launches Tecentriq Intravenous Infusion 840 mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Japan

Shots:

  • Tecentriq (atezolizumab, q2w) Intravenous Infusion 840mg has been listed on the NIH reimbursement price list and launched by Chugai as an optimal formulation to treat PD-L1-positive hormone receptor-negative and HER2-negative inoperable or recurrent BC
  • The P-III IMpassion130 study involve assessing of Tecentriq + nab-paclitaxel (albumin-bound) vs nab-paclitaxel (albumin-bound) in patients with unresectable LA/metastatic TNBC prior not treated with systemic therapy for mBC
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1receptors and has received MHLW’s approval for this indication and dosage form on Sep 20, 2019

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical | Image: Business Insider

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post